FindTrial
Sign In

A prospective multi-center single-arm study of EBV-associated lymphoproliferative disease by X-ray irradiated allogeneic lymphocyte infusion

A prospective multi-center single-arm study of EBV-associated lymphoproliferative disease by X-ray irradiated allogeneic lymphocyte infusion

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17011907
Enrollment
Unknown
Registered
2017-07-08
Start date
2017-07-07
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory or relapse EBV-associated lymphoproliferative disease

Interventions

single group:DLI

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. EBV-associated lymphoproliferative diseases are confirmed by pathology histomorphology and immunohistochemistry, and EBER positive are determined using in situ hybridization method; 2. EB virus DNA in peripheral blood is positive; 3. routine treatment of peripheral blood EBV is invalid; 4. Eastern Cancer Collaboration (ECOG) Physical Status Rating is 0-2.

Exclusion criteria

Exclusion criteria: 1. patients had a severe transfusion reaction or transfusion related to GVHD; 2. patients had hepatitis B active infection or HIV antibody positive; 3. patients had any other serious active or psychiatric disorder; 4. patients are already pregnant or breastfeeding; 5. Comprehensive assessment of life expectancy is less than 3 months.

Design outcomes

Primary

MeasureTime frame
EBV-DNA;—

Countries

China

Contacts

Public ContactXinan Cen

Peking University First Hospital

xinancen@botmail.com+8610 83575680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026